AR006514A1 - Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende - Google Patents
Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprendeInfo
- Publication number
- AR006514A1 AR006514A1 ARP960103427A AR10342796A AR006514A1 AR 006514 A1 AR006514 A1 AR 006514A1 AR P960103427 A ARP960103427 A AR P960103427A AR 10342796 A AR10342796 A AR 10342796A AR 006514 A1 AR006514 A1 AR 006514A1
- Authority
- AR
- Argentina
- Prior art keywords
- macrolide
- producing
- pharmaceutical composition
- produce
- inclusive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a un macrólido el cual tiene: i) las posiciones 2 a 6 inclusive, del anillo macrocíclico que se proporcionan por un residuo de ácidopiperidazinilcarboxílico; y/o ii)las posiciones 7 a 9 inclusive, del anillo macrocíclicoque se proporcionan por un residuo alfa-aminoácido aromático;y/o iii) las posiciones 10 a 12 inclusive, del anillo macrocíclico que se proporcionan por un residuo alfa-aminoácido alifático, en forma libreo protegida, o una sal del mismo.Además, s e refiere al uso de dicho macrólido para la preparación de un medicamento para uso como inmunosupresor, al uso dedicho macrólido como un reactivo en un inmunoensayo de desplazamiento para una ciclosporina u otros compuestos que unenciclofilina , a un proceso paraproducir dicho macrólido, a un aislado biológicamente puro de la cepa Streptomyces sp A92-308110 (DSM 9954) o un mutante, recombinante o formamodificada del mismo, el cual es capaz de producir dichomacrólido, y a una composición farmacéutica que comprende a dicho macrólido en asociación con undiluyente o portador farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9513596.8A GB9513596D0 (en) | 1995-07-04 | 1995-07-04 | Organic compounds |
| GBGB9515495.1A GB9515495D0 (en) | 1995-07-28 | 1995-07-28 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006514A1 true AR006514A1 (es) | 1999-09-08 |
Family
ID=26307320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103427A AR006514A1 (es) | 1995-07-04 | 1996-07-03 | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0836616A1 (es) |
| JP (1) | JPH11509092A (es) |
| KR (1) | KR19990028724A (es) |
| CN (1) | CN1193979A (es) |
| AR (1) | AR006514A1 (es) |
| AU (1) | AU708004B2 (es) |
| BR (1) | BR9609324A (es) |
| CA (1) | CA2224715A1 (es) |
| CO (1) | CO4750713A1 (es) |
| CZ (1) | CZ424297A3 (es) |
| HU (1) | HUP9802320A3 (es) |
| IL (1) | IL122844A0 (es) |
| NO (1) | NO980016L (es) |
| PL (1) | PL324346A1 (es) |
| SK (1) | SK498A3 (es) |
| TR (1) | TR199800001T1 (es) |
| WO (1) | WO1997002285A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) * | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| US7368423B1 (en) * | 2001-12-05 | 2008-05-06 | The Scripps Research Institute | Composition and method for treating chronic allograft rejection |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| RU2427372C2 (ru) | 2005-06-17 | 2011-08-27 | Новартис Аг | Применение санглиферина для лечения вируса гепатита с |
| US8067024B2 (en) | 2006-02-10 | 2011-11-29 | Medtronic Vascular, Inc. | Medical devices to prevent or inhibit restenosis |
| CN101289440B (zh) * | 2007-06-29 | 2010-08-25 | 中国热带农业科学院热带生物技术研究所 | 一种多烯大环类化合物及其制备方法与应用 |
| CN102224242B (zh) * | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| BR112012019866A8 (pt) | 2010-02-09 | 2017-12-26 | Biotica Tech Limited | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| CA3028414C (en) | 2010-12-20 | 2021-01-26 | Neurovive Pharmaceutical Ab | Sanglifehrin derivatives and methods for their production |
| JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| GB201118334D0 (en) | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
| PT2861604T (pt) * | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| MX2014014768A (es) * | 2012-06-08 | 2015-05-11 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae. |
| EP3541388A1 (en) | 2016-11-18 | 2019-09-25 | Neurovive Pharmaceutical AB | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9318144D0 (en) * | 1993-09-01 | 1993-10-20 | Sandoz Ltd | Organic compounds |
| WO1995015328A1 (en) * | 1993-11-30 | 1995-06-08 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
-
1996
- 1996-07-03 AR ARP960103427A patent/AR006514A1/es unknown
- 1996-07-04 WO PCT/EP1996/002952 patent/WO1997002285A1/en not_active Application Discontinuation
- 1996-07-04 CZ CZ974242A patent/CZ424297A3/cs unknown
- 1996-07-04 JP JP9504832A patent/JPH11509092A/ja active Pending
- 1996-07-04 PL PL96324346A patent/PL324346A1/xx unknown
- 1996-07-04 AU AU65193/96A patent/AU708004B2/en not_active Ceased
- 1996-07-04 CN CN96196487A patent/CN1193979A/zh active Pending
- 1996-07-04 IL IL12284496A patent/IL122844A0/xx unknown
- 1996-07-04 TR TR1998/00001T patent/TR199800001T1/xx unknown
- 1996-07-04 SK SK4-98A patent/SK498A3/sk unknown
- 1996-07-04 EP EP96924886A patent/EP0836616A1/en not_active Withdrawn
- 1996-07-04 BR BR9609324A patent/BR9609324A/pt not_active Application Discontinuation
- 1996-07-04 HU HU9802320A patent/HUP9802320A3/hu unknown
- 1996-07-04 CO CO96034982A patent/CO4750713A1/es unknown
- 1996-07-04 KR KR1019980700022A patent/KR19990028724A/ko not_active Application Discontinuation
- 1996-07-04 CA CA002224715A patent/CA2224715A1/en not_active Abandoned
-
1998
- 1998-01-02 NO NO980016A patent/NO980016L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU708004B2 (en) | 1999-07-29 |
| JPH11509092A (ja) | 1999-08-17 |
| TR199800001T1 (xx) | 1998-04-21 |
| BR9609324A (pt) | 1999-05-25 |
| AU6519396A (en) | 1997-02-05 |
| CZ424297A3 (cs) | 1998-04-15 |
| KR19990028724A (ko) | 1999-04-15 |
| IL122844A0 (en) | 1998-08-16 |
| PL324346A1 (en) | 1998-05-25 |
| SK498A3 (en) | 1998-07-08 |
| NO980016L (no) | 1998-03-02 |
| MX9800217A (es) | 1998-07-31 |
| NO980016D0 (no) | 1998-01-02 |
| HUP9802320A2 (hu) | 1999-02-01 |
| HUP9802320A3 (en) | 1999-03-29 |
| EP0836616A1 (en) | 1998-04-22 |
| CN1193979A (zh) | 1998-09-23 |
| CA2224715A1 (en) | 1997-01-23 |
| CO4750713A1 (es) | 1999-03-31 |
| WO1997002285A1 (en) | 1997-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006514A1 (es) | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende | |
| ATE92080T1 (de) | Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15. | |
| KR100203556B1 (ko) | 신규의 사이클로스포린 | |
| ES2093658T3 (es) | Polipeptido ciclico con actividad antibiotica, procedimiento para su preparacion y cultivo puro de una cepa de coelomycetes. | |
| DK0431350T3 (da) | Ny polypeptidforbindelse og fremgangsmåde til fremstilling deraf | |
| DK366889A (da) | Peptidderivat | |
| DE69003168D1 (de) | Isolierung und Strukturbestimmung des zytostatischen linearen depsipeptiden Dolastatin 13 und Dehydrodolastatin 13. | |
| ES2149276T3 (es) | Imidazo(4,5-c)piridin-4-aminas. | |
| KR890000518A (ko) | 시클릭 펩톨라이드 | |
| GB2380675A (en) | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | |
| BR9810002A (pt) | Preparação de <244>1-at nativa purificada cromatograficamente, processo para a preparação da mesma, e, utilização de um material de suporte | |
| EA200100347A1 (ru) | Метод и композиция для лечения и профилактики туберкулеза | |
| Fusetani et al. | Nazumamide A, a thrombin-inhibitory Tetrapeptide, from a marine sponge, theonella sp. | |
| ES2097736T3 (es) | Peptido ciclico con actividad antagonista de sustancia p y sustancia k. | |
| NO960372L (no) | Gener som koder for forgrenet alfa-ketosyredehydrogenasekompleks fra Streptomyces avermitilis | |
| ES2084599T3 (es) | Metodo para purificar antitrombina iii y preparacion de antitrombina iii que contiene dicha antitrombina iii. | |
| AR004165A1 (es) | Una sal de diclavulanato de bis-(2-dialquilaminoalquil)-eter; un procedimiento para preparar la misma; y una composicion farmaceutica que la contiene | |
| GB8802229D0 (en) | Ws-9326 & its derivatives | |
| IT1313624B1 (it) | Procedimento per la sintesi del ritonavir | |
| AU7386094A (en) | T-lymphocyte-containing pharmaceutical composition for treating infections | |
| JPH0338280B2 (es) | ||
| KR920018226A (ko) | 생리활성 캉글레마이신 c, 그 제조방법 및 용도 | |
| GB8928811D0 (en) | An activator for damaged neurocytes for the prevention and treatment of disease |